Stifel analyst Stephen Manaker lowered the firm’s price target on Medical Properties Trust to $12 from $14 and keeps a Buy rating on the shares. Stifel believes attractive valuations and double-digit dividend yield "more than offset earnings volatility," the analyst tells investors. The firm believes the company’s story remains complex, but tenant issues are being resolved and there is now a buyer for the Australian assets.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MPW:
- Medical Properties Trust cuts FY23 normalized FFO view to $1.50-$1.65
- Medical Properties Trust reports Q1 normalized FFO 37c, consensus 37c
- Medical Properties Trust put volume heavy and directionally bearish
- MPW Earnings this Week: How Will it Perform?
- Medical Properties Trust initiated with an Equal Weight at Wells Fargo
